I certainly hope they prove to be good points in a few weeks time...
I also forgot to mention the prospect of a GvHD partnership, as explicitly referenced on the CC. This is purely speculative, but it would be huge if they knew that something was in the works to be finalized in the next few weeks. Imagine this potential chain of events:
- Announce (assumed) successful interim primary endpoints, along with completed combo enrollment. That sets a time frame for top line results.
- Assuming some price action on successful interim data, R/S and uplist. You have full combo data coming to help combat any short pressure or gains taking.
- Once on a major exchange, announce a GvHD partnership with an established biotech company. If CYDY wasn't previously on analysts' and institutional investors' maps, it certainly would be then.
- Announce (assumed positive) combo results and an update on mono enrollment once you have analysts' attention.
Obviously this is highly speculative and contains assumptions, but I refuse to say that it's far-fetched. We've been given short-term time frames on interim and complete combo primary endpoint data, and we know they're in talks with potential GvHD partners. I think the assumptions can be supported by data that we've already seen. If they could align events like that and the noted assumptions hold true... look out above.
And if anyone is concerned about whether or not management is thinking this strategically, you have my permission to forward them a link to this post. I'd be happy for them to borrow as they see fit!